1. Israel Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ERIKA CARMEL-TECH LTD

ERIKA CARMEL-TECH LTD

TTASE:ERKA
45.90
ILA
-2.10
(-4.37%)
1.98BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.86
1.23
2.07
2.34
1.2
0.72
0.91
0.9
- -
Basic EPS, GAAP
0.06
0.06
0.3
-0.53
-0.78
-0.46
-0.23
-0.14
- -
Free Cash Flow per Basic Share
0.11
0.12
0.41
-0.72
-0.8
-0.22
-0.1
0.03
- -
Dividend per Share
- -
- -
0.07
0.12
- -
- -
- -
- -
- -
Book Value per Share
- -
0.08
0.22
2.13
1.02
0.57
0.36
0.23
0.23
Tangible Book Value per Share
- -
0.08
0.21
2.12
1.02
0.57
0.36
0.23
0.23
Basic Weighted Avg Shares
41
41
41
41
42
42
42
42
42
Sales/Revenue/Turnover
36
51
86
97
50
30
38
37
- -
Operating Margin (%)
11.41
8.93
20.33
-19.57
-57.21
-68.02
-23.39
-11.83
- -
Depreciation Expense
1
1
2
3
3
2
2
2
- -
Net Income, GAAP
3
2
12
-22
-33
-19
-9
-6
- -
Effective Tax Rate (%)
26.49
37.17
25.39
- -
- -
- -
- -
- -
- -
Profit Margin (%)
7.14
4.61
14.53
-22.52
-64.71
-64.32
-24.95
-15.67
- -
Working Capital
- -
4
5
73
35
18
11
7
7
LT Debt
- -
11
14
14
6
3
2
1
1
Total Equity
- -
3
9
88
43
24
15
10
10
Return on Invested Capital (%)
- -
- -
52.58
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
58.97
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
206.39
-44.95
-49.82
-57.9
-48.86
-47.15
- -

Capital Structure

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
- -
- -
20

Working Capital

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
28
26
24
Cash, Cash Equivalents & STI
4
5
4
Accounts Receivable, Net
6
3
4
Inventories
16
16
14
Total Current Liabilities
17
16
17
Payables & Accruals
- -
- -
- -
ST Debt
1
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
142.85%
-34.91%
Free Cash Flow
- -
-104.16%
-131.05%
Net Income, GAAP
- -
-71.11%
-38.19%
Sales/Revenue/Turnover
- -
-10.07%
-1.64%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
30
2024
- -
- -
38
2025
- -
- -
37

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.46
2024
- -
- -
-0.23
2025
- -
- -
-0.14

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Moti Navon
Full Time Employees
43
Sector
Health technology
Industry
Medical specialties
Address
Nahum Hat 5 Haifa HA Israel 3508504
IPO Date
Aug 1, 2021
Website
bcurelaser.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Erika Carmel-Tech Ltd, a Tel Aviv Stock Exchange-listed entity, operates as a medical device company focused on the development, production, marketing, sales and distribution of home-use soft laser therapy devices. The company markets its products under the B-Cure Laser brand family, including models designed to address pain management, orthopedic conditions, wounds and inflammations, with portable, lightweight devices intended for domestic use. The group also develops and offers device solutions for animal treatment. Headquarters are in Israel, and the company pursues sales domestically in Israel and internationally across Europe, North America and other regions under the B-Cure Laser trade name. Founded in 2010, Erika Carmel-Tech Ltd maintains a multi-market footprint, with operating subsidiaries and distribution arrangements to support global availability of its laser-based therapeutic devices. The company emphasizes compact, user-friendly hardware paired with soft laser technology, supported by a product portfolio that spans multiple device generations and configurations aligned to consumer and veterinary health needs. Key subsidiaries and restructurings reflect a strategic focus on expanding direct and partner-driven channels, regulatory compliance, and ongoing product enhancements to broaden clinical applicability and home-use adoption. The latest notable changes include strategic partnerships and pipeline expansions within the home-use medical device segment, ongoing product launches to extend the B-Cure Laser lineup, and efforts to broaden geographic reach through intensified distribution networks and regional partnerships. The firm operates within the broader medical equipment and consumer health technology space, targeting individual consumers seeking at-home therapeutic options, as well as veterinary markets requiring non-invasive laser-based treatment for animals.